Long-term mortality in patients with end-stage renal disease undergoing hemodialysis and peritoneal dialysis: a propensity score matching retrospective study

Figures & data

Table 1. Patients characteristics.

	Before propensity-matching			After propensity-matching
characteristics	HD (n = 690)	PD (n = 629)	P	HD (n = 461)	PD (n = 461)	P
Ethnicity (Han)	608 (88.1%)	553 (87.9%)	0.912	405 (87.9%)	406 (88.1%)	0.919
Age (years)	47.57 (17.22)	51.22 (16.55)	0.001	49.38 (16.91)	40.83 (16.40)	0.682
Male(%)	405 (58.7%)	318 (51.6%)	0.030	239 (51.8%)	245 (53.9%)	0.692
Weight (kg)	62.98 (9.53)	63.03 (9.27)	0.930	62.98 (9.68)	63.14 (9.31)	0.801
BMI (kg/m^2)	25.96 (3.37)	25.50 (3.61)	0.018	25.64 (3.52)	25.71 (3.54)	0.770
Urine (mL)	227.26 (118.6)	256.25 (221.23)	0.036	237.26 (120.35)	255.25 (211.40)	0.056
PD (n, %)
GN	267 (38.7%)	250 (39.7%)	0.846	187 (40.6%)	185 (40.1%)	0.919
DN	207 (30.0%)	194 (30.8%)		134 (29.1%)	139 (30.2%)
HRD	136 (19.7%)	121 (19.2%)		85 (18.4%)	88 (19.1%)
Others	80 (11.6%)	64 (10.2%)		55 (11.9%)	49 (10.6%)
HB (g/L)	84.13 (20.59)	85.18 (20.33)	0.355	84.94 (10.53)	84.29 (21.09)	0.625
ALB (g/L)	28.99 (3.53)	29.05 (3.44)	0.798	28.99 (3.61)	28.93 (3.42)	0.782
NT-proBNP (pg/mL)	14877.88 (19608.3)	16641.38 (27405.3)	0.032	14987.88 (19647.2)	16470.38 (25401.7)	0.061
PTH (pg/mL)	689.53 (365.8)	709.23 (372.47)	0.333	704.76 (373.49)	693.63 (365.47)	0.648
GFR (mL/min)	7.97 (2.78)	8.59 (3.11)	0.034	8.62 (2.70)	8.58 (2.87)	0.792
Scr (umol/L)	761.02 (244.9)	736.81 (190.11)	0.019	751.02 (231.05)	739.94 (178.41)	0.058
BUN (mmol/L)	31.03 (9.50)	29.18 (7.18)	0.027	30.83 (8.60)	29.68 (7.20)	0.071
Comorbidities
CAD	460 (66.7%)	485 (77.1%)	0.001	324 (70.3%)	319 (69.2%)	0.720
HF	496 (71.9%)	453 (72%)	0.957	334 (72.5%)	334 (72.5%)	1.000
DM	383 (55.5%)	360 (57.2%)	0.528	260 (56.4%)	257 (55.7%)	0.842
Cancer	47 (6.8%)	50 (7.9%)	0.429	11 (16.7%)	80 (17.4%)	0.793
HBP	378 (54.8%)	344 (54.7%)	0.973	255 (55.3%)	253 (54.9%)	0.895
COPD	97 (14.1%)	48 (7.6%)	0.001	39 (8.5%)	42 (9.1%)	0.727
PVD	61 (8.8%)	106 (16.9%)	0.001	51 (11.1%)	53 (11.5%)	0.835
MI	68 (9.9%)	94 (14.9%)	0.005	52 (11.3%)	53 (11.5%)	0.917

BMI, body mass index; PD, primary disease; GN, glomerulonephritis; DN, diabetes nephropathy; HRD, hypertensive renal disease; HB, hemoglobin; ALB, albumin; NT-proBNP, N-terminal pro brain natriuretic peptide; PTH, parathyroid hormone; GFR, glomerular filtration rate; Scr, Serum creatinine; BUN, blood urea nitrogen; CAD, coronary artery disease; HF, heart failure; DM, diabetes mellitus; HBP, high blood pressure; COPD, chronic obstructive pulmonary disease; PVD, peripheral vascular diseases; MI, myocardial infarction.

Figure 1. The mortality rate in patients with end-stage renal disease.

Figure 2. Kaplan–Meier curves showing survival of patients with end-stage renal disease. There was a significant difference between the PD and HD groups in terms of patient survival rate during follow-up. After a mean follow-up of 120 months, 82.4% of patients in the HD group and 72.7% in the PD group survived.

Table 2. Multivariate analysis for factors associated with all-cause death in ESRD.

Variables	Adjusted OR for all patients (95% CI)	P value	Variables	Adjusted OR for HD (95% CI)	P value	Variables	Adjusted OR for PD (95% CI)	P value
Age	1.018 (1.008–1.028)	0.001	Age	1.018 (1.002–1.035)	0.030	Age	1.015 (1.002–1.028)	0.021
Weight	0.966 (0.949–0.983)	0.001	HBP	1.994 (1.140–3.489)	0.016	Weight	0.947 (0.925–0.970)	0.001
HBP	1.489 (1.060–2.090)	0.022	PTH	1.001 (1.000–1.002)	0.005
Scr	0.996 (0.990–1.000)	0.047	Scr	0.999 (0.998–1.000)	0.054
Cancer	1.838 (1.233–2.741)	0.003	PVD	2.844 (1.424–5.685)	0.003

HRD, hypertensive renal disease; Scr, Serum creatinine; PTH, parathyroid hormone; PVD, peripheral vascular disease.